Volume 74, Issue 5 , Pages 1592-1599, 1 August 2009
B1 Sequence–Based Real-Time Quantitative PCR: A Sensitive Method for Direct Measurement of Mouse Plasma DNA Levels After Gamma Irradiation
Purpose
Current biodosimetric techniques for determining radiation exposure have inherent delays, as well as quantitation and interpretation limitations. We have identified a new technique with the advantage of directly measuring circulating DNA by amplifying inter-B1 regions in the mouse genome, providing a sensitive method for quantitating plasma DNA.
Methods and Materials
Real-time quantitative polymerase chain reaction (PCR) was used to detect levels of DNA by amplifying inter-B1 genomic DNA in plasma samples collected at 0–48 h from mice receiving 0–10 Gy total- or partial-body irradiation (137Cs γ-ray source at ≈1.86 Gy/min; homogeneity: ± 6.5%).
Results
The correlation coefficient between DNA levels and the threshold cycle value (CT) was 0.996, and the average recoveries of DNA in the assay were 87%. This assay revealed that when BALB/c mice were exposed to 10 Gy total-body irradiation (TBI), plasma DNA levels gradually increased beginning at 3 h after irradiation, peaked at 9 h, and returned to baseline within 48 h. Increased plasma DNA levels were also detected following upper-torso or lower-torso partial-body irradiation; however, TBI approximately doubled those plasma DNA levels at the same radiation dose. This technique therefore reflects total body cell damage. The advantages of this assay are that DNA extraction is not required, the assay is highly sensitive (0.002 ng), and results can be obtained within 2.5 h after collection of plasma samples.
Conclusions
A radiation dose–dependent increase of plasma DNA was observed in the dose range from 2 to 10 Gy, suggesting that plasma DNA may be a useful radiation biomarker and adjunct to existing cell-based assays.
qPCR, Irradiation, Inter-B1, Alu, DNA, Plasma
To access this article, please choose from the options below
This research was supported by the Centers for Medical Countermeasures against Radiation program, U19-AI067733, National Institute of Allergy and Infectious Diseases (NIAID).
Conflict of interest: The authors acknowledge that a conflict of interest exists; Dr. Lurong Zhang and Dr. Paul Okunieff are co-owners of the technology development company DiaCarta, which owns intellectual property related to the measurement of radiation exposure using circulating DNA.
PII: S0360-3016(09)00427-1
doi:10.1016/j.ijrobp.2009.03.009
© 2009 Elsevier Inc. All rights reserved.
Volume 74, Issue 5 , Pages 1592-1599, 1 August 2009
